PERSONAL DATA PROTECTION INFORMATION

 (Newsletter subscription through Pharma Mar Web site)

Data Controller PHARMA MAR, S.A.,  CIF: A-78267176,

Mailing Address: Avda. De los Reyes, 1, 28770 – Colmenar Viejo (Madrid), España

Data Protection Officer contact: dpo@pharmamar.com

Purpose of processing Electronic communication services provision.

 

Storage Period Personal data will be kept in the system for an indefinite period of time as long as no request is made for their deletion by the interested party.
Lawful basis for processing Consent if you have subscribed to our newsletter and you may withdraw your consent at any time by writing to the address below.

By providing us with your e-mail address or any other means of electronic communication, you expressly consent to the use of such means for the aforementioned purpose.

Categories of recipients (data disclosures, data processors, international transfers) No data will be disclosed to third parties without your consent.

There will be no international transfer of your personal data

Rights You can exercise, if you wish, your rights of access, rectification and suppression of data, as well as request that the processing of your personal data be limited, oppose it, request the portability of your data, if necessary, by writing to Pharma Mar at mailing address mentioned above and including the `Ref. Data Protection’ and a photocopy of a valid ID in this communication.

You can also contact us through the e-mail address dpo@pharmamar.com

In the event that you does not obtain a satisfactory response, Pharma Mar hereby informs of your right to submit a complaint to the Spanish Data Protection Agency, ( www.agdp.es)

For further and detailed information on Data Protection, please visit our website:  https://www.pharmamar.com

Accionistas e Inversores

Mantente al día sobre la información financiera de la Compañía, sobre la acción, sobre los hechos relevantes que se comunican a la CNMV o sobre nuestra cartera de productos, entre otros.

Productos de Oncología

PharmaMar tiene una importante cartera preclínica de compuestos y un potente programa de I+D. Desarrolla y comercializa YONDELIS® en Europa y dispone de otros tres compuestos en desarrollo clínico: plitidepsina, PM1183 y PM184.

Sala de Prensa

Si necesitas información sobre la actividad de la compañía, resultados de ensayos clínicos, imágenes corporativas o incluso archivos multimedia, accede a la sala de prensa.